ArticleGene therapy2014
Efficient siRNA transfection to the inner ear through the intact round window by a novel proteidic delivery technology in the chinchilla.
Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Ultrasound-Mediated Lysozyme Microbubbles Targeting NOX4 Knockdown Alleviate Cisplatin-Exposed Cochlear Hair Cell Ototoxicity.International journal of molecular sciences · 2024Article
- Identification of Target Proteins Involved in Cochlear Hair Cell Progenitor Cytotoxicity following Gentamicin Exposure.Journal of clinical medicine · 2022Article
- Advances and challenges in adeno-associated viral inner-ear gene therapy for sensorineural hearing loss.Molecular therapy. Methods & clinical development · 2021Review
- RNA Secondary Structure as a First Step for Rational Design of the Oligonucleotides towards Inhibition of Influenza A Virus Replication.Pathogens (Basel, Switzerland) · 2020Review
- Suppression of Connexin 43 Leads to Strial Vascular Hyper-Permeability, Decrease in Endocochlear Potential, and Mild Hearing Loss.Frontiers in physiology · 2020Article
- Genetic Therapies for Hearing Loss: Accomplishments and Remaining Challenges.Neuroscience letters · 2019Review
- Cochlear Gene Therapy.Cold Spring Harbor perspectives in medicine · 2019Review
- Local Drug Delivery for Prevention of Hearing Loss.Frontiers in cellular neuroscience · 2019Review
- Potential of Gene and Cell Therapy for Inner Ear Hair Cells.BioMed research international · 2018Review
- Intravenous rAAV2/9 injection for murine cochlear gene delivery.Scientific reports · 2017Article
- Ototoxicity of Divalent Metals.Neurotoxicity research · 2016Review
- Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects.Scientific reports · 2016Article
- The spread of adenoviral vectors to central nervous system through pathway of cochlea in mimetic aging and young rats.Gene therapy · 2015Article
- A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.Biotechnology advances · 2015Review
- Progresses towards safe and efficient gene therapy vectors.Oncotarget · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of small-interfering RNA (siRNA) has great potential for the development of drugs designed to knock down the expression of damage- or disease-causing genes. However, because of the high molecular weight and negative charge of siRNA, it is restricted from crossing the blood-cochlear barrier, which limits the concentration and size of molecules that are able to gain access to cells of the inner ear. Intratympanic approaches, which deliver siRNA to the middle ear, rely on permeation through the round window for access to the structures of the inner ear. We developed an innovative siRNA delivery recombination protein, TAT double-stranded RNA-binding domains (TAT-DRBDs), which can transfect Cy3-labeled siRNA into cells of the inner ear, including the inner and outer hair cells, crista ampullaris, macula utriculi and macula sacculi, through intact round-window permeation in the chinchilla in vivo, and there were no apparent morphological damages for the time of observation. We also found that Cy3-labeled siRNA could directly enter spiral ganglion neurons and the epithelium of the stria vascularis independently; however, the mechanism is unknown. Therefore, as a non-viral vector, TAT-DRBD is a good candidate for the delivery of double-stranded siRNAs for treating various inner ear ailments and preservation of hearing function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.